Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2023)
14 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 10, 2023
Slide 1: GaRP Clinical Trial Discussion
NOVEMBER 2023 GaRP Clinical Trial Discussion ANATARA LIFESCIENCES LTD
Slide 2: Clinical trial - Irritable Bowel Syndrome
Clinical trial - Irritable Bowel Syndrome ROBUST CLINICAL TRIAL TO VALIDATE THE EFFECTIVENESS OF GARP STAGE 1 STAGE 2 50-100 Patients (randomised, double- blind placebo-controlled) Cohort 1 ~33% Patients on placebo Cohort 1 61 Interim Analysis ~50% Patients on placebo Final Results Readout Patients
Slide 3: GaRP ANR-Bromelain
GaRP ANR-Bromelain Reduces pro-inflammatory cytokines & ONE PRODUCT, MULTIPLE BENEFITS serotonin; promotes healing via mucin genes; reduces attachment some bacteria. Patent Protected Scientifically designed for the relief and management of background IBS symptoms and the rejuvenation of GIT dynamics
Slide 4: Phase II Clinical trial
Phase II Clinical trial Irritable Bowel Syndrome ROBUST CLINICAL TRIAL TO VALIDATE THE EFFECTIVENESS OF GARP Title Dose Determination and Efficacy Evaluation of the Endpoints Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS patients: A Randomized, Double-blind, Placebo controlled ✓ No
Slide 5: Recruitment - Stage
Recruitment - Stage 1 The most prevalent exclusion criterium was the IBS-SSS score > 45% of participants deemed ineligible during pre-screening Other exclusion factors IBS-SSS < 175 IBS-SSS > 350 GARP CLINICAL TRIAL DISCUSSION ANATARA LIFESCIENCES 04
Slide 6: Results Placebo (N=20)
Stage 1- Clinical Trial Results Placebo (N=20) DEMOGRAPHICS 30% Median Age N: 61 70% 37 Female: 40 Male: 21 Low Dose (N=20) Female Male 45% Female Male 55% High dose (N=21) 19% 34% Female Male GARP CLINICAL TRIAL DISCUSSION ANATARA LIFESCIENCES 66% 81% Female Male 05
Slide 7: Adverse Events
Stage 1- Clinical Trial View "Low Dose" was the predicted , recommended dose from pre-clinical work. “High Dose" is double the Low Dose /Recommended Dose .The High Dose cohort was added to ensure that the dose of complementary medicine was not sub-therapeutic in the IBS trial and so ADVERSE EVENTS t
Slide 8: Results
Stage 1- Clinical Trial Results Placebo n=20 Low Dose n=20 High Dose n=21 Baseline 265 240 280 PRIMARY ENDPOINTS Week 1 240 210 255 Week 2 195 145 180 Week 4 185 110 160 Week 6 220 100 140 Stage 1 IBS Clinical Trial Week 8 170 105 140 • Number of Patients: Placebo: 20 / Low Dose: 20 / High Dose: 21
Slide 9: Results
Stage 1- Clinical Trial Results SECONDARY ENDPOINTS Improvement in IBS Quality of Life (IBS-QoL) Score • Low Dose resulted: ✓ A 10 pt + reduction is considered clinically meaningful QoL Scoring Placebo Low Dose High Dose Baseline score 86.8 85.2 92.3 GARP CLINICAL TRIAL DISCUSSION Week 2 82.4 80.6 8
Slide 10: Results
Stage 1- Clinical Trial Results SECONDARY ENDPOINTS ANXIETY SCORE Improvement in Hospital Anxiety & Depression Score (HADS) • Low Dose Resulted in: ✓ Anxiety Score: from borderline abnormal to normal ✓ Depression Score: remained normal throughout ✓ Placebo group deteriorated to abnormal range Anxiet
Slide 11: Clinical Trial Discussion
Stage 1 Clinical Trial Discussion Why does anxiety improve? Direct and indirect effects are easily postulated because of the MOA (Mechanism of Action of the drug). Firstly, improved symptoms as measured by IBS-SSS lessens concern over day –to –day control and management leading to a reduction in bac
Slide 12: Clinical Trial Discussion
Stage 1 Clinical Trial Discussion How does GaRP ( to be known as “Anajuve” ) restore and maintain the integrity of What is the gut-brain axis? the gastrointestinal lining as a barrier? How does GaRP/Anajuve therefore have a beneficial effect on the gut-brain axis? This is the two-way biochemical sig
Slide 13: IBS in America Survey
IBS in America Survey USE OF TREATMENTS FOR IRRITABLE BOWEL SYNDROME AND PATIENT SATISFACTION, BASED ON IBS IN AMERICA SURVEY Trial Details Use and satisfaction of various IBS treatments The publication Significant 3,254 “Highlights the need opportunity for an IBS sufferers (Rome III criteria) GaRP
Slide 14: Contact Us
David Brookes Dirk van Dissel Executive Chair Investor Relations Contact Us +61 0411 712 579 Candour Advisory ANATARA LIFESCIENCES LTD www.anataralifesciences.com dirk@candouradvisory.com.au
Anatara Lifesciences — Shareholder Meeting (November 2023) on 6ix